{"url_path":"/sec/sgmt/8-k/2026-06-12/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-073431-index.html","accession_number":"0001104659-26-073431","cik":"0001400118","ticker":"SGMT","issuer_name":"Sagimet Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-073431-index.html","primary_entity_key":"0001400118","primary_entity_name":"Sagimet Biosciences Inc."},"word_count":320,"has_tables":true,"body_markdown":"false\n0001400118\n\n0001400118\n\n2026-06-12\n2026-06-12\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d)**\n\n**of the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nJune 12, 2026**\n\n \n\n \n\n \n\n**SAGIMET BIOSCIENCES INC.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n \n\n \n\n \n\n**Delaware**\n**001-41742**\n**20-5991472**\n\n**(State or other jurisdiction**\n\n**of incorporation)**\n**(Commission\nFile Number)**\n**(I.R.S. Employer**\n\n**Identification No.)**\n\n \n\n**Sagimet Biosciences Inc.**\n\n**155\nBovet Road****, Suite 303****,**\n\n**San\nMateo****, California****94402**\n\n**(Address of principal executive offices, including\nzip code)**\n\n \n\n**(650****)\n561-8600**\n\n**(Registrant’s telephone number, including\narea code)**\n\n \n\n**Not Applicable**\n\n**(Former Name or Former Address, if Changed\nSince Last Report)**\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨\nPre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨\nPre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle\nof each class\nTrade\n\nSymbol(s)\nName\nof each exchange on which registered\n\nSeries A\nCommon Stock, $0.0001 par value per share\nSGMT\nThe Nasdaq\nGlobal Market\n\n \n\nIndicate by check mark whether the registrant is\nan emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2\nof the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company x\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}